IXICO PLC - Interim results for the six months ended 31 March 2026

Ixico PLC delivered a strong H1 2026 investor update, reporting 23% revenue growth to £3.9 million, ahead of full-year guidance of 15%, driven by rising demand for its neurology-focused imaging CRO services and expanding Alzheimer’s and Parkinson’s disease pipeline. The company achieved a record £18.1 million order book, up 31% year-on-year, providing 95% visibility on FY26 revenue guidance and supporting confidence in sustained long-term growth. Gross margins improved to 53% through operational leverage, automation, and higher-value Phase II and III clinical trial work, while EBITDA losses narrowed despite continued investment in technology and commercial expansion. Following a £10 million capital raise, Ixico is accelerating its “Innovate, Lead, Scale” growth strategy, investing in AI-driven neuroimaging analytics, platform automation, and recurring revenue opportunities through its proprietary ICSI platform. Management highlighted strategic partnerships, including a collaboration with Medidata, alongside growing traction with major pharma, biotech, and diagnostic clients. The company is also advancing its “TechBio” strategy to commercialize scalable software and data products targeting the broader clinical trials and neurodegenerative disease markets. With increasing US presence, expanding key opinion leader support, and strong momentum in Alzheimer’s disease programs, Ixico positioned itself as a leading neuroimaging analytics and clinical research technology provider focused on sustainable revenue growth, margin expansion, and long-term shareholder value creation.